Cobra Biologics Receives the Queen’s Award for Enterprise in International Trade
April 21 2018 - 04:00AM
Business Wire
The UK’s most prestigious business award granted in recognition
of outstanding achievement in the export of services for gene and
immunotherapy products.
Cobra Biologics (“Cobra”) a leading international contract
development and manufacturing organisation (“CDMO”), today
announced that it has been awarded the Queen’s Award 2018 for
Enterprise, in the International Trade category. The prestigious
award is in recognition of Cobra’s commercial success in providing
services to its global customer base.
Now in their 53rd year, the Queen’s Awards have a long history
of recognising exceptional UK businesses and Cobra will be
attending a reception at Buckingham Palace followed by a
presentation of the Award by a representative of Her Majesty The
Queen at Cobra’s UK facility later in the year.
Cobra has a 20 year track record of supporting the life science
industry with contract development and manufacturing of
biopharmaceuticals, from preclinical through to clinical trials and
commercial supply and currently exports over 85% of its services
from its facilities based in the UK and Sweden.
Cobra’s UK based GMP approved facility is a globally recognised
centre of excellence for the development and production of
biological material to support both gene- and immuno-therapy. In
April 2017, Cobra announced a £15 million gene therapy expansion
plan, to meet the increased demand from both plasmid DNA and viral
vectors for Phase III and Commercial supply to support both
existing and new customer requirements in the development of
revolutionary disease therapies.
Peter Coleman, Chief Executive of Cobra Biologics, commented:
“I am immensely proud of what Cobra has achieved over the last
few years, culminating in the Queen’s Award. International Trade is
vitally important for Cobra and the work that we do is challenging
and requires a committed work force whose skills and dedication
attract business from all over the world. I would like also to
thank the Office for Life Science, Innovate UK and the Department
for International Trade for their support of our expansion plans in
the UK.”
ENDS
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180421005032/en/
For Cobra BiologicsSarah JefferyZyme
CommunicationsE-mail: sarah.jeffery@zymecommunications.comPhone:
+44 (0)7771 730919